Association of RAS/BRAF Status and Prognosis of Metastatic Colorectal Cancer: Analysis of 1002 Consecutive Cases

Background This study aimed to analyze the association of RAS/BRAF status and the prognosis of patients with metastatic colorectal cancer (mCRC) based on multi-disciplinary team (MDT) treatment mode. Methods The study retrospectively analyzed 1002 consecutive mCRC patients with different tumor RAS/B...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of surgical oncology 2022-06, Vol.29 (6), p.3593-3603
Hauptverfasser:	Tang, Wentao, Liu, Yu, Ji, Meiling, Liu, Tianyu, Chen, Yijiao, Zhuang, Aobo, Mao, Yihao, Chang, Wenju, Wei, Ye, Ren, Li, Xu, Jianmin
Format:	Artikel
Sprache:	eng
Schlagworte:	Antigens CA-19-9 Antigen Cancer Carcinoembryonic antigen Colonic Neoplasms Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - pathology Humans Medical prognosis Medicine Medicine & Public Health Metastases Metastasis Mutants Mutation Mutation rates Oncology Patients Prognosis Proto-Oncogene Proteins B-raf - genetics Proto-Oncogene Proteins p21(ras) - genetics Rectal Neoplasms Retrospective Studies Surgery Surgical Oncology Survival Translational Research Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background This study aimed to analyze the association of RAS/BRAF status and the prognosis of patients with metastatic colorectal cancer (mCRC) based on multi-disciplinary team (MDT) treatment mode. Methods The study retrospectively analyzed 1002 consecutive mCRC patients with different tumor RAS/BRAF status at Zhongshan Hospital Fudan University from April 2012 to December 2018. The association of RAS/BRAF status with clinicopathologic features and prognosis was analyzed. Results The mutation rate was 42.3% (424/1002) for RAS and 5.0% (50/1002) for BRAF. The RAS and BRAF mutations were mutually exclusive of each other. An association of RAS/BRAF status with sex ( P
ISSN:	1068-9265 1534-4681
DOI:	10.1245/s10434-021-11302-5